Half-Life of Namenda (Memantine)
The elimination half-life of memantine (Namenda) is approximately 60-80 hours in humans with normal renal function. 111
Pharmacokinetic Profile
Memantine exhibits the following key pharmacokinetic characteristics:
- Peak plasma concentration (Tmax): 3-7 hours after oral administration 11
- Terminal elimination half-life: 60-80 hours in healthy adults 111
- Time to steady state: Approximately 3 days of regular dosing 2
- Excretion: Predominantly renal (48% unchanged in urine), with minimal hepatic metabolism 11
Impact of Renal Impairment
The half-life increases substantially with declining renal function, which is clinically significant given memantine's primary renal elimination:
- Mild renal impairment (CrCl >50-80 mL/min): Half-life increases by 18% 13
- Moderate renal impairment (CrCl 30-49 mL/min): Half-life increases by 41% 13
- Severe renal impairment (CrCl 5-29 mL/min): Half-life increases by 95% (reaching approximately 124 hours) 13
Dose reduction is required in severe renal impairment to prevent drug accumulation and potential adverse effects. 11
Clinical Implications
The long half-life of memantine has several important clinical consequences:
- Steady-state Cmax/Cmin ratio: Approximately 1.5, indicating stable drug levels throughout the dosing interval 4
- Dosing frequency: The extended half-life allows for once or twice-daily dosing
- Drug accumulation risk: Conditions that alkalinize urine (pH >8) can reduce clearance by approximately 80%, leading to drug accumulation 11
- Discontinuation effects: Due to the long half-life, memantine takes considerable time to wash out after discontinuation
Species Differences (Important Caveat)
Animal pharmacokinetics cannot be extrapolated to humans. In rats and mice, memantine has a much shorter half-life (<4 hours) compared to the 60-80 hours in humans, with clearance rates 13 and 4.5 times higher than glomerular filtration rate respectively. 45 This represents a critical difference when interpreting preclinical studies.
Human pharmacokinetic data should always be prioritized over animal data when making clinical decisions about memantine dosing and timing.